ONDERZOEK NAAR EFFECT VAN BEVACIZUMAB BEHANDELING BIJ MELANOMEN M.B.V. MOLECULAIRE BEELDVORMING.

Recruiting

• Conditions: melanoma, imaging, VEGF, bevacizumab

• Registration Number: NL-OMON21967
• Lead Sponsor: MCG

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

1. Surgically resectable melanoma, stage III or IV;

2. WHO performance status 0-2;

Exclusion Criteria

1. Prior chemotherapy or biological therapy for metastatic disease;

2. Prior radiotherapy on the involved area;

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To identify biological effects of bevacizumab therapy and to visualize distribution kinetics and uptake of 111In-bevacizumab in the micro-environment of the tumor with gamma-camera imaging.